Handelsbanken Fonder
REGN icon

Handelsbanken Fonder’s Regeneron Pharmaceuticals REGN Stock Holding History

Handelsbanken Fonder’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.6M Sell
52,328
-72,708
-58% -$49.5M 0.09% 183
2026
Q1 		$96.6M Buy
125,036
+24,330
+24% +$18.6M 0.32% 55
2025
Q4 		$77.7M Buy
100,706
+37,657
+60% +$25.6M 0.23% 72
2025
Q3 		$35.5M Buy
63,049
+12,547
+25% +$7.09M 0.11% 172
2025
Q2 		$26.5M Buy
50,502
+3,998
+9% +$2.23M 0.09% 202
2025
Q1 		$29.5M Sell
46,504
-1,650
-3% -$1.13M 0.12% 166
2024
Q4 		$34.3M Sell
48,154
-35,486
-42% -$29.8M 0.13% 152
2024
Q3 		$87.9M Sell
83,640
-3,461
-4% -$3.85M 0.35% 52
2024
Q2 		$91.5M Sell
87,101
-18,026
-17% -$17.5M 0.4% 43
2024
Q1 		$101M Buy
105,127
+10,087
+11% +$9.59M 0.44% 42
2023
Q4 		$83.5M Sell
95,040
-33,986
-26% -$28M 0.41% 46
2023
Q3 		$106M Sell
129,026
-4,532
-3% -$3.56M 0.59% 29
2023
Q2 		$96M Sell
133,558
-18,731
-12% -$14.4M 0.51% 36
2023
Q1 		$125M Sell
152,289
-28,290
-16% -$21.3M 0.72% 20
2022
Q4 		$130M Sell
180,579
-26,041
-13% -$19.2M 0.82% 18
2022
Q3 		$142M Buy
206,620
+12,300
+6% +$7.74M 0.95% 16
2022
Q2 		$115M Sell
194,320
-3,420
-2% -$2.22M 0.75% 21
2022
Q1 		$138M Buy
197,740
+14,000
+8% +$8.86M 0.77% 21
2021
Q4 		$116M Buy
183,740
+29,317
+19% +$18M 0.57% 29
2021
Q3 		$93.5M Buy
154,423
+134,000
+656% +$83.2M 0.49% 39
2021
Q2 		$11.4M Sell
20,423
-4,934
-19% -$2.5M 0.06% 304
2021
Q1 		$12M Buy
25,357
+637
+3% +$310K 0.07% 263
2020
Q4 		$11.9M Sell
24,720
-7,288
-23% -$3.93M 0.07% 252
2020
Q3 		$17.9M Sell
32,008
-13,335
-29% -$8.09M 0.13% 163
2020
Q2 		$28.3M Buy
45,343
+35,343
+353% +$20.1M 0.24% 93
2020
Q1 		$4.88M Buy
+10,000
New +$4.12M 0.11% 146
2017
Q1 		– Sell
-2,000
Closed -$734K – 175
2016
Q4 		$734K Buy
+2,000
New +$761K 0.02% 152
2016
Q1 		– Sell
-9,223
Closed -$5.01M – 507
2015
Q4 		$5.01M Buy
+9,223
New +$5M 0.1% 188

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Handelsbanken Fonder's REGN Position: Q2 2026 in Review

Handelsbanken Fonder reduced its Regeneron Pharmaceuticals (REGN) stake by 58% in Q2 2026, selling an estimated $49.5M and leaving 52,328 shares worth $32.6M. The position accounts for 0.09% of the portfolio, ranked #183.

Handelsbanken Fonder first reported a position in REGN in Q4 2015 and has held it in 28 quarters since. The position peaked at $142M in Q3 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Handelsbanken Fonder held 52,328 shares of Regeneron Pharmaceuticals worth $32.6M as of Q2 2026.
  • Handelsbanken Fonder sold 72,708 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $49.5M.
  • Regeneron Pharmaceuticals made up 0.09% of Handelsbanken Fonder's portfolio in Q2 2026, its #183 holding.
  • Handelsbanken Fonder first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • Handelsbanken Fonder's Regeneron Pharmaceuticals position peaked at $142M in Q3 2022.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.